2022
First report of safety/tolerability and preliminary antitumor activity of CAN-2409 in inadequate responders to immune checkpoint inhibitors for stage III/IV NSCLC.
Aggarwal C, Haas A, Gordon S, Mehra R, Lee P, Bestvina C, Maldonado F, Velcheti V, Herbst R, Bell S, Gillmor R, Manzanera A, Matheny C, Aguilar-Cordova E, Aguilar L, Barone F, Tak P, Sterman D. First report of safety/tolerability and preliminary antitumor activity of CAN-2409 in inadequate responders to immune checkpoint inhibitors for stage III/IV NSCLC. Journal Of Clinical Oncology 2022, 40: 9037-9037. DOI: 10.1200/jco.2022.40.16_suppl.9037.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsStage III/IV NSCLCProgressive diseaseClinical responseAdvanced NSCLCEvaluable patientsCheckpoint inhibitorsInjected tumorsDisease-positive lymph nodesNon-injected lesionsSafety/tolerabilitySubset of patientsT cell infiltrationPreliminary antitumor activityPreliminary clinical dataTumor cell lysisMedicine clinical trialsRational combination approachesIntra-tumoral deliveryStable diseaseData cutoffDisease stabilizationImmunologic biomarkersOral valacyclovirMedian duration
2020
Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC
Herbst RS, Arkenau HT, Bendell J, Arrowsmith E, Wermke M, Soriano A, Penel N, Santana-Davila R, Bischoff H, Chau I, Mi G, Wang H, Rasmussen E, Ferry D, Chao BH, Paz-Ares L. Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC. Journal Of Thoracic Oncology 2020, 16: 289-298. PMID: 33068794, DOI: 10.1016/j.jtho.2020.10.004.Peer-Reviewed Original ResearchConceptsProgression-free survivalTumor proportion scoreMedian progression-free survivalTreatment-related adverse eventsPD-L1 expressionT-cell signatureCD274 gene expressionAdverse eventsPhase 1a/b trialPD-L1 tumor proportion scoreHigh PD-L1 expressionManageable safety profileMedian overall survivalObjective response ratePD-L1 positivityFirst-line therapyOverall survival ratePD-L1 immunohistochemistryCohort EPembrolizumab treatmentPFS ratesExpansion cohortClinical responseOverall survivalEfficacy signals
2017
Measurement of PD-1, TIM-3 and LAG-3 protein in non-small cell lung carcinomas (NSCLCs) with acquired resistance to PD-1 axis blockers.
Datar I, Mani N, Henick B, Wurtz A, Kaftan E, Herbst R, Rimm D, Gettinger S, Politi K, Schalper K. Measurement of PD-1, TIM-3 and LAG-3 protein in non-small cell lung carcinomas (NSCLCs) with acquired resistance to PD-1 axis blockers. Journal Of Clinical Oncology 2017, 35: e14611-e14611. DOI: 10.1200/jco.2017.35.15_suppl.e14611.Peer-Reviewed Original ResearchNon-small cell lung carcinomaTim-3PD-1LAG-3T cellsInhibitory receptorsAdvanced non-small cell lung carcinomaPD-1 axis blockadeHigh TIM-3Immune suppressive pathwaysImmune inhibitory receptorsCell lung carcinomaMembranous staining patternPre-treatment samplesWhole tissue sectionsWhole tumor areaClinical responseMost patientsAxis blockadeLow levelsLung carcinomaT lymphocytesMultiplex immunofluorescenceHigh levelsSuppressive pathways
2014
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014, 515: 563-567. PMID: 25428504, PMCID: PMC4836193, DOI: 10.1038/nature14011.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedB7-H1 AntigenBiomarkersChemokine CX3CL1Clinical ProtocolsCTLA-4 AntigenDisease-Free SurvivalFemaleGene Expression Regulation, NeoplasticHumansImmunotherapyLymphocytes, Tumor-InfiltratingMaleMiddle AgedNeoplasmsTreatment OutcomeYoung Adult
2007
First-in-human study of AMG 386, a selective angiopoietin1/2-neutralizing peptibody, in adult patients with advanced solid tumors
Rosen L, Hong D, Chap L, Kurzrock R, Garcia A, Rasmussen E, Nguyen L, Hwang Y, Storgard C, Herbst R. First-in-human study of AMG 386, a selective angiopoietin1/2-neutralizing peptibody, in adult patients with advanced solid tumors. Journal Of Clinical Oncology 2007, 25: 3522-3522. DOI: 10.1200/jco.2007.25.18_suppl.3522.Peer-Reviewed Original ResearchAMG 386Advanced solid tumorsAdverse eventsStable diseaseTumor responseHuman studiesGrade 2Solid tumorsDCE-MRIMinor clinical responseSignificant vascular effectsSerum CA 125Treatment-related toxicityDose-limiting toxicityFurther clinical studiesEvaluable patientsEvaluable subjectsPeripheral edemaRECIST criteriaAdult patientsClinical responseProgressive diseaseWeekly administrationVascular effectsCA 125
2003
Targeting the epidermal growth factor receptor: prognostic and clinical implications
Herbst R. Targeting the epidermal growth factor receptor: prognostic and clinical implications. European Journal Of Cancer Supplements 2003, 1: 9-15. DOI: 10.1016/s1359-6349(03)80015-0.Peer-Reviewed Original ResearchEpidermal growth factor receptorGrowth factor receptorEGFR tyrosine kinase inhibitor gefitinibFactor receptorTyrosine kinase inhibitor gefitinibCell lung cancerKinase inhibitor gefitinibPerformance statusClinical responseSkin toxicityPrognostic valueDisease characteristicsLung cancerSurrogate markerClinical trialsNovel anticancer agentsInhibitor gefitinibClinical implicationsGefitinibAntitumour activityBiological markersPromising targetExpression levelsTumorigenic processAnticancer agentsA phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
Herbst RS, Hammond LA, Carbone DP, Tran HT, Holroyd KJ, Desai A, Williams JI, Bekele BN, Hait H, Allgood V, Solomon S, Schiller JH. A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Clinical Cancer Research 2003, 9: 4108-15. PMID: 14519633.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAngiogenesis InhibitorsAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCarcinoma, Non-Small-Cell LungCholestanolsDisease-Free SurvivalFemaleHumansInfusions, IntravenousLactatesLung NeoplasmsMaleMiddle AgedNeoplasm StagingPaclitaxelPatient SelectionPleural EffusionSurvival AnalysisTime FactorsConceptsNon-small cell lung cancerCell lung cancerLung cancerDay 1Continuous infusionChemotherapy-naive non-small cell lung cancerAdvanced non-small cell lung cancerPhase I/IIa studyPhase I/IIa trialPhase II doseDose-limiting toxicityPartial tumor responseFive-day infusionEffective therapeutic strategyPatient survival dataEvaluable patientsStable diseaseStage IIIBStarting doseClinical responseCombination regimenCytotoxic chemotherapyIIa studyIIa trialMedian survival